Clinical Trial Update: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the anti-inflammatory effects of Letermovir (Prevymis) in adults with HIV infection and asymptomatic cytomegalovirus on suppressive A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• HIV Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Cytomegalovirus | Phase 2 | Status: TERMINATED | Results posted: 2025-03-04